Supplementary Table S3 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
Year: 2024
Type: supplementary-materials
Abstract: Antiproliferative effect of RLY-4008 and pan-FGFRi in human tumor cell lines
Authors: Vivek Subbiah, Vaibhav Sahai, Dejan Maglic, Kamil Bruderek, B. Barry. Toure, Songping Zhao, Roberto Valverde, Patrick J. O'Hearn, Demetri T. Moustakas, Heike Schonherr, Nastaran Gerami-Moayed, Alexander M. Taylor, Brandi M. Hudson, Damian J. Houde, Debjani Pal, Lindsey Foster, Hakan Gunaydin, Pelin Ayaz, Dina A. Sharon, Lipika Goyal, Alison M. Schram, Suneel Kamath, Cori Ann Sherwin, Oleg Schmidt-Kittler, Kai Yu Jen, Fabien Ricard, Beni B. Wolf, David E. Shaw, Donald A. Bergstrom, James Watters, Jessica B. Casaletto
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4402802648